Search hospitals > Texas > Houston
Lyndon Baines Johnson General Hospital
Claim this profileHouston, Texas 77026
Global Leader in Cancer
Global Leader in Adenocarcinoma
Conducts research for Recurrence
Conducts research for Breast Cancer
Conducts research for Endometrioid Carcinoma
102 reported clinical trials
15 medical researchers
Summary
Lyndon Baines Johnson General Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Adenocarcinoma, Recurrence, Breast Cancer, Endometrioid Carcinoma and other specialties. Lyndon Baines Johnson General Hospital is involved with conducting 102 clinical trials across 225 conditions. There are 15 research doctors associated with this hospital, such as Shannon Westin, MD, Aung Naing, MD, Michael J Overman, MD, and Vicente Valero, MD.Area of expertise
1Cancer
Global LeaderStage IV
HER2 positive
Stage III
2Adenocarcinoma
Global LeaderStage IV
Stage III
Stage II
Top PIs
Shannon Westin, MDM D Anderson Cancer Center5 years of reported clinical research
Expert in Ovarian Cancer
Studies Endometrial Cancer
19 reported clinical trials
35 drugs studied
Aung Naing, MDMD Anderson Cancer Center1 year of reported clinical research
Expert in Tumors
Expert in Solid Tumors
25 reported clinical trials
46 drugs studied
Michael J Overman, MDM D Anderson Cancer Center3 years of reported clinical research
Studies Solid Tumors
Studies Colorectal Cancer
10 reported clinical trials
20 drugs studied
Vicente Valero, MDM D Anderson Cancer Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
21 drugs studied
Clinical Trials running at Lyndon Baines Johnson General Hospital
Breast Cancer
Rectal Cancer
Prostate Cancer
Ovarian Cancer
Fallopian Tube Cancer
Colorectal Cancer
Endometrial Adenocarcinoma
Anal Cancer
Peritoneal Cancer
Recurrence
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Lyndon Baines Johnson General Hospital?
Lyndon Baines Johnson General Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Adenocarcinoma, Recurrence, Breast Cancer, Endometrioid Carcinoma and other specialties. Lyndon Baines Johnson General Hospital is involved with conducting 102 clinical trials across 225 conditions. There are 15 research doctors associated with this hospital, such as Shannon Westin, MD, Aung Naing, MD, Michael J Overman, MD, and Vicente Valero, MD.